Tyra Biosciences, Inc. (TYRA)
Every FINRA and SEC series the site collects for Tyra Biosciences, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq.
9.4M
Short interest
settlement 2026-08-31
27.1
Days to cover
-2.6% vs prior
80.9%
Short share of volume
2026-09-17
5,599
Fails to deliver
settlement 2026-08-28
Wed 4 Nov
Next earnings
estimated; last year 2025-11-05
$20K
Insider flow, 90 days
1 buys, 0 sells
As of 2026-09-17.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 31 August 2026, short interest in TYRA is 9,440,216 shares, up 193,281 shares over the last month. Over the last 48 readings it ranged from 1,756,303 shares (31 October 2024) to 11,924,900 shares (30 June 2026). At the reported average volume of 348K shares a day that is 27.1 days to cover, a crowded short.
Embed this chartkeeps the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/tyra" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-31 | 9,440,216 | -2.6% | 347,850 | 27.14 |
| 2026-08-14 | 9,689,392 | +4.8% | 766,180 | 12.65 |
| 2026-07-31 | 9,246,935 | -6.9% | 518,736 | 17.83 |
| 2026-07-15 | 9,930,770 | -16.7% | 640,837 | 15.50 |
| 2026-06-30 | 11,924,900 | +20.9% | 1,273,015 | 9.37 |
| 2026-06-15 | 9,866,801 | +6.3% | 1,072,493 | 9.20 |
| 2026-05-29 | 9,281,430 | +15.1% | 707,583 | 13.12 |
| 2026-05-15 | 8,065,431 | +4.6% | 637,653 | 12.65 |
| 2026-04-30 | 7,708,671 | -0.0% | 1,153,312 | 6.68 |
| 2026-04-15 | 7,709,241 | -6.7% | 1,013,045 | 7.61 |
| 2026-03-31 | 8,264,887 | +20.6% | 1,041,198 | 7.94 |
| 2026-03-13 | 6,853,153 | +20.9% | 1,656,105 | 4.14 |
| 2026-02-27 | 5,667,913 | +10.2% | 754,760 | 7.51 |
| 2026-02-13 | 5,144,732 | +2.6% | 752,172 | 6.84 |
| 2026-01-30 | 5,013,172 | -1.2% | 766,499 | 6.54 |
| 2026-01-15 | 5,073,265 | -12.4% | 609,223 | 8.33 |
| 2025-12-31 | 5,791,320 | +36.6% | 543,765 | 10.65 |
| 2025-12-15 | 4,238,532 | +2.2% | 466,449 | 9.09 |
| 2025-11-28 | 4,146,608 | -5.2% | 720,993 | 5.75 |
| 2025-11-14 | 4,375,041 | -7.0% | 237,625 | 18.41 |
| 2025-10-31 | 4,706,779 | -18.6% | 285,072 | 16.51 |
| 2025-10-15 | 5,782,614 | -2.3% | 174,202 | 33.19 |
| 2025-09-30 | 5,915,988 | -0.6% | 178,901 | 33.07 |
| 2025-09-15 | 5,952,493 | +0.6% | 226,894 | 26.23 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 17 September 2026, the short share of TYRA volume is 80.9%, up 3.6 points over the last five sessions. Over the last 52 readings it ranged from 31.0% (2 September 2026) to 88.1% (8 July 2026). The latest reading is 14.0 points above the 30-session average of 66.9%, on 167K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-17 | 135K | 167K | 80.9% | 3,698 |
| 2026-09-16 | 296K | 416K | 71.3% | 1,740 |
| 2026-09-15 | 400K | 467K | 85.5% | 50 |
| 2026-09-14 | 950K | 1.1M | 84.3% | 0 |
| 2026-09-11 | 731K | 850K | 86.0% | 0 |
| 2026-09-10 | 1.1M | 1.5M | 77.3% | 40,759 |
| 2026-09-09 | 1.3M | 2.9M | 42.9% | 52,653 |
| 2026-09-08 | 368K | 533K | 69.1% | 20 |
| 2026-09-04 | 679K | 856K | 79.3% | 6,145 |
| 2026-09-03 | 138K | 185K | 74.6% | 45,072 |
| 2026-09-02 | 69K | 223K | 31.0% | 0 |
| 2026-09-01 | 116K | 176K | 65.7% | 0 |
| 2026-08-31 | 64K | 97K | 66.4% | 0 |
| 2026-08-28 | 44K | 71K | 61.4% | 0 |
| 2026-08-27 | 41K | 97K | 42.3% | 0 |
| 2026-08-26 | 46K | 91K | 50.7% | 0 |
| 2026-08-25 | 61K | 103K | 59.3% | 0 |
| 2026-08-24 | 76K | 119K | 63.9% | 0 |
| 2026-08-21 | 69K | 102K | 67.5% | 0 |
| 2026-08-20 | 85K | 112K | 75.7% | 0 |
| 2026-08-19 | 61K | 83K | 74.3% | 0 |
| 2026-08-18 | 103K | 141K | 73.2% | 0 |
| 2026-08-17 | 157K | 319K | 49.1% | 100 |
| 2026-08-14 | 128K | 212K | 60.4% | 300 |
| 2026-08-13 | 114K | 192K | 59.3% | 218 |
| 2026-08-12 | 104K | 171K | 60.7% | 0 |
| 2026-08-11 | 194K | 245K | 79.2% | 0 |
| 2026-08-10 | 103K | 155K | 66.8% | 0 |
| 2026-08-07 | 268K | 353K | 75.9% | 100 |
| 2026-08-06 | 245K | 341K | 71.7% | 2,637 |
Fails to deliver
SEC, by settlement date. JSONAs of 28 August 2026, the fails-to-deliver balance in TYRA is 5,599 shares, up 1,834 shares over the last settlement date. Over the last 52 readings it ranged from 2 shares (9 January 2026) to 484,466 shares (5 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-28 | 5,599 | $26.13 | $146K |
| 2026-08-27 | 3,765 | $26.22 | $99K |
| 2026-08-25 | 313 | $26.09 | $8K |
| 2026-08-17 | 13,404 | $25.29 | $339K |
| 2026-08-14 | 25,757 | $25.02 | $644K |
| 2026-08-12 | 2,001 | $25.18 | $50K |
| 2026-08-05 | 2,087 | $32.53 | $68K |
| 2026-08-03 | 30 | $31.88 | $956 |
| 2026-07-31 | 536 | $33.06 | $18K |
| 2026-07-30 | 4,168 | $31.11 | $130K |
| 2026-07-28 | 12,918 | $31.06 | $401K |
| 2026-07-27 | 461 | $30.63 | $14K |
| 2026-07-16 | 5 | $32.38 | $162 |
| 2026-07-15 | 1,535 | $32.88 | $50K |
| 2026-07-09 | 1,004 | $32.57 | $33K |
| 2026-07-02 | 49,845 | $29.41 | $1.5M |
| 2026-07-01 | 55,459 | $31.94 | $1.8M |
| 2026-06-30 | 30,552 | $32.11 | $981K |
| 2026-06-29 | 32,703 | $31.88 | $1.0M |
| 2026-06-26 | 28,839 | $30.94 | $892K |
| 2026-06-25 | 1,450 | $30.37 | $44K |
| 2026-06-24 | 587 | $30.06 | $18K |
| 2026-06-23 | 1,205 | $30.14 | $36K |
| 2026-06-22 | 3,511 | $28.32 | $99K |
| 2026-06-15 | 7,447 | $26.99 | $201K |
| 2026-06-12 | 467 | $25.57 | $12K |
| 2026-06-08 | 24,311 | $26.64 | $648K |
| 2026-05-29 | 11 | $32.68 | $359 |
| 2026-05-28 | 11,605 | $33.17 | $385K |
| 2026-05-27 | 304 | $33.59 | $10K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at TYRA reported 1 open-market buy worth $20K in the last 90 days and no open-market sells. Clustered voluntary buying is historically the stronger insider signal because insiders buy for one reason. Latest filing: Fuhrman Alan (Chief Financial Officer) on 2026-09-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Fuhrman Alan | Chief Financial Officer | Grant | 951 | $9.13 | $9K | 37K |
| 2026-09-15 | Rueb Yuliya | Vice President, Finance (PAO) | Grant | 3K | $9.13 | $27K | 11K |
| 2026-09-15 | Harris Todd | President and CEO | Grant | 864 | $9.13 | $8K | 1.4M |
| 2026-09-09 | Verjee Rehan | n/a | Buy | 972 | $20.58 | $20K | 972 |
| 2026-05-05 | Warner Douglas J | Chief Medical Officer | Grant | 25K | $0.00 | $0 | 25K |
| 2026-05-05 | Rueb Yuliya | Vice President, Finance (PAO) | Grant | 8K | $0.00 | $0 | 43K |
| 2026-05-05 | Harris Todd | President and CEO | Grant | 79K | $0.00 | $0 | 1.4M |
| 2026-05-05 | Fuhrman Alan | Chief Financial Officer | Grant | 20K | $0.00 | $0 | 36K |
| 2026-05-05 | Ashar Bhavesh | Chief Operating Officer | Grant | 15K | $0.00 | $0 | 15K |
| 2026-03-26 | KAPLAN GILLA | n/a | Disposition | 53K | $37.75 | $2.0M | 28K |
| 2026-03-26 | KAPLAN GILLA | n/a | Option exercise | 53K | $2.25 | $120K | 81K |
| 2026-03-25 | KAPLAN GILLA | n/a | Sell | 14K | $36.97 | $529K | 28K |
| 2026-03-25 | KAPLAN GILLA | n/a | Option exercise | 14K | $2.25 | $32K | 43K |
| 2026-03-13 | Harris Todd | President and CEO | Grant | 1K | $9.13 | $13K | 1.4M |
| 2026-03-13 | Fuhrman Alan | Chief Financial Officer | Grant | 1K | $9.13 | $13K | 16K |
| 2026-02-12 | Bensen Daniel | Chief Discovery Officer | Sell | 6K | $33.37 | $196K | 147K |
| 2026-02-12 | Bensen Daniel | Chief Discovery Officer | Sell | 2K | $31.50 | $67K | 153K |
| 2026-01-12 | Bensen Daniel | Chief Discovery Officer | Sell | 1K | $29.08 | $30K | 155K |
| 2026-01-12 | Bensen Daniel | Chief Discovery Officer | Sell | 7K | $28.44 | $199K | 156K |
| 2025-12-19 | MORE ROBERT J | n/a | Sell | 10K | $25.00 | $250K | 3.8M |
| 2025-12-12 | Bensen Daniel | Chief Discovery Officer | Sell | 8K | $22.64 | $181K | 163K |
| 2025-11-21 | MORE ROBERT J | n/a | Sell | 247K | $20.25 | $5.0M | 3.8M |
| 2025-11-19 | Bensen Daniel | Chief Operating Officer | Sell | 50K | $16.32 | $815K | 171K |
| 2025-11-18 | Bensen Daniel | Chief Operating Officer | Sell | 76K | $16.07 | $1.2M | 221K |
| 2025-11-17 | Bensen Daniel | Chief Operating Officer | Sell | 2K | $17.07 | $26K | 297K |
| 2025-11-17 | Bensen Daniel | Chief Operating Officer | Sell | 19K | $16.11 | $299K | 298K |
| 2025-11-14 | Bensen Daniel | Chief Operating Officer | Sell | 110K | $16.02 | $1.8M | 317K |
| 2025-11-13 | Bensen Daniel | Chief Operating Officer | Sell | 1K | $16.00 | $18K | 427K |
| 2025-09-15 | Fuhrman Alan | Chief Financial Officer | Grant | 701 | $9.13 | $6K | 15K |
| 2025-06-18 | KAPLAN GILLA | n/a | Sell | 10K | $9.78 | $94K | 28K |
| 2025-06-17 | KAPLAN GILLA | n/a | Sell | 10 | $10.35 | $104 | 38K |
| 2025-06-16 | RA CAPITAL MANAGEMENT, L.P. | n/a | Buy | 12K | $10.13 | $120K | 10.3M |
| 2025-06-16 | KAPLAN GILLA | n/a | Sell | 7K | $10.38 | $71K | 38K |
| 2025-06-13 | RA CAPITAL MANAGEMENT, L.P. | n/a | Buy | 120K | $10.20 | $1.2M | 10.2M |
| 2025-06-13 | KAPLAN GILLA | n/a | Sell | 15K | $10.31 | $155K | 45K |
| 2025-06-12 | RA CAPITAL MANAGEMENT, L.P. | n/a | Buy | 31K | $10.20 | $319K | 10.1M |
| 2025-06-12 | KAPLAN GILLA | n/a | Sell | 30K | $10.31 | $309K | 60K |
| 2025-06-09 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Buy | 187K | $10.19 | $1.9M | 10.1M |
| 2025-06-05 | Kolchinsky Peter | Director,TenPercentOwner | Buy | 213K | $10.04 | $2.1M | 9.9M |
| 2025-06-04 | Kolchinsky Peter | Director,TenPercentOwner | Buy | 998K | $9.63 | $9.6M | 9.7M |
| 2025-03-14 | Fuhrman Alan | Chief Financial Officer | Grant | 1K | $9.78 | $12K | 14K |
| 2025-03-14 | Harris Todd | President and CEO | Grant | 1K | $9.78 | $12K | 1.4M |
| 2025-02-05 | Kjellson Nina S | Director | Sell | 4K | $13.76 | $48K | 444K |
| 2025-02-05 | Kjellson Nina S | Director | Sell | 2K | $13.76 | $26K | 3.7M |
| 2025-01-23 | Kjellson Nina S | Director | Sell | 5K | $16.26 | $78K | 3.7M |
| 2025-01-21 | Kjellson Nina S | Director | Sell | 4K | $16.36 | $65K | 3.7M |
| 2025-01-17 | Kjellson Nina S | Director | Sell | 13K | $16.40 | $210K | 3.7M |
| 2025-01-17 | Kjellson Nina S | Director | Sell | 461 | $16.40 | $8K | 447K |
| 2025-01-16 | Kjellson Nina S | Director | Sell | 835 | $16.29 | $14K | 448K |
| 2025-01-16 | Kjellson Nina S | Director | Sell | 7K | $16.29 | $113K | 3.7M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for TYRA worth $11.0M at the prices reported; 0 in the last 90 days worth $0. Latest: GILLA KAPLAN filed on 2026-03-25 to sell 14,295 shares ($529K) from 2026-03-25.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-03-25 | GILLA KAPLANDirector | 14K | $529K | 0.027% | 2026-03-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-12 | Daniel BensenOfficer | 8K | $283K | 0.015% | 2026-03-12 | Merrill Lynch |
| 2026-02-12 | Daniel BensenOfficer | 8K | $262K | 0.015% | 2026-02-12 | Merrill Lynch |
| 2026-01-12 | Daniel BensenOfficer | 8K | $232K | 0.015% | 2026-01-12 | Merrill Lynch |
| 2025-12-12 | Daniel BensenOfficer | 8K | $180K | 0.015% | 2025-12-12 | Merrill Lynch |
| 2025-11-21 | Alta Partners NextGen Fund II, L.P.Affiliate | 257K | $5.4M | 0.481% | 2025-11-21 | Merrill Lynch |
| 2025-11-18 | Daniel BensenOfficer | 125K | $2.0M | 0.233% | 2025-11-18 | Merrill Lynch |
| 2025-11-17 | Daniel BensenOfficer | 20K | $320K | 0.038% | 2025-11-17 | Merrill Lynch |
| 2025-11-14 | Daniel BensenOfficer | 86K | $1.4M | 0.162% | 2025-11-14 | Merrill Lynch |
| 2025-11-13 | Daniel BensenOfficer | 25K | $400K | 0.047% | 2025-11-13 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON49 holders above 5% have filed on TYRA, 4 on Schedule 13D (active intent). The largest reported stake is Peter Kolchinsky at 19.9% of the class (14,130,492 shares), filed 2026-09-17 for an event on 2026-09-15.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-17 | 13D/Ano. 7 | Peter Kolchinskyparent holding company, individual | 14.1M | 19.9% | 2026-09-15 |
| 2026-09-17 | 13D/Ano. 7 | RA Capital Management, L.P.investment adviser, partnership | 14.1M | 19.9% | 2026-09-15 |
| 2026-09-17 | 13D/Ano. 7 | Rajeev Shahparent holding company, individual | 14.1M | 19.9% | 2026-09-15 |
| 2026-09-17 | 13D/Ano. 7 | RA Capital Healthcare Fund, L.P.partnership | 12.1M | 17.2% | 2026-09-15 |
| 2026-09-17 | 13G | Paradigm BioCapital Advisors LPpartnership | 3.5M | 5.8% | 2026-09-10 |
| 2026-09-17 | 13G | Senai Asefaw, M.D.individual | 3.5M | 5.8% | 2026-09-10 |
| 2026-09-17 | 13G | Paradigm BioCapital Advisors GP LLCother entity | 3.5M | 5.8% | 2026-09-10 |
| 2026-09-17 | 13G | Paradigm BioCapital International Fund Ltd.corporation | 3.1M | 5.1% | 2026-09-10 |
| 2026-08-14 | 13G/Ano. 2 | Nextech VI Oncology SCSppartnership | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Nextech VI GP S.a. r.l.other entity | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Ian Charoubindividual | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Costas Constantinidesindividual | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Rocco Sgobboindividual | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dapice Joshua J.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dreyfuss, Philip D.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dunn Hannah E.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Gehani, Varun N.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Giauque, Nicolasparent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Husen, Avner A.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Kim, David T.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Linn, Michael G.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Luo Patrick (Cheng)parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Roberts, Jr., Thomas G.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Saito Edric C.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Short Daniel S.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Spokes, Andrew J. M.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Warren, John R.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Wehrly, Mark C.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Management, L.L.C.investment adviser, other entity | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-07-30 | 13G | BlackRock, Inc.parent holding company | 3.0M | 5.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 2 | JANUS HENDERSON GROUP PLCparent holding company | 3.9M | 7.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Michael Kramarzparent holding company, individual | 2.5M | 4.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Commodore Capital LPinvestment adviser, partnership | 2.5M | 4.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Robert Egen Atkinsonparent holding company, individual | 2.5M | 4.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Commodore Capital Master LPpartnership | 2.5M | 4.2% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 1 | Todd Harrisindividual | 2.9M | 4.8% | 2026-03-31 |
| 2026-05-12 | 13G/Ano. 1 | Dapice Joshua J.individual | 3.6M | 6.6% | 2026-03-31 |
13F holders
Tracked managers holding TYRA at their latest 13F. JSON6 of the 30 tracked managers held TYRA at their latest 13F, $33.3M in total at quarter-end prices. Two Sigma Investments is the largest at $14.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 450K | $14.4M | 0.01% | +348K |
| Citadel Advisors | 2026-06-30 | 278K | $8.9M | 0.00% | +231K |
| Millennium Management | 2026-06-30 | 203K | $6.5M | 0.00% | +88K |
| Fisher Asset Management | 2026-06-30 | 60K | $1.9M | 0.00% | +31K |
| AQR Capital Management | 2026-06-30 | 30K | $954K | 0.00% | +430 |
| D. E. Shaw & Co. | 2026-06-30 | 20K | $645K | 0.00% | -12K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Tyra Biosciences, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Tyra Biosciences, Inc. (TYRA), SEC CIK 1863127, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-31.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-17.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-28.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-03-25.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-09-17.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K Item 2.02 (full-text search)EDGAR full-text search read twice a day; the estimate is last year's date plus 52 weeks. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1863127Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 18 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- TEAMAtlassian Corp
- CVNACARVANA CO.
- CRMSalesforce, Inc.
- METAMeta Platforms, Inc.
- UTHRUNITED THERAPEUTICS Corp
- CRWVCoreWeave, Inc.
- RCGRENN Fund, Inc.
- ANETArista Networks, Inc.
- DDOGDatadog, Inc.
- NETCloudflare, Inc.
- DELLDell Technologies Inc.
- GOOGAlphabet Inc.
- CRWDCrowdStrike Holdings, Inc.
- TPLTexas Pacific Land Corp
- MRNAModerna, Inc.
- COINCoinbase Global, Inc.
- NOWServiceNow, Inc.
- MORNMorningstar, Inc.
- CPIXCUMBERLAND PHARMACEUTICALS INC
- DASHDoorDash, Inc.
- ZMZoom Communications, Inc.
- TDGTransDigm Group INC
- UBERUber Technologies, Inc
- PCTYPaylocity Holding Corp
Datasets
Frequently Asked Questions
How much of TYRA is sold short?
What is TYRA's daily short volume?
Does TYRA have fails to deliver?
Are TYRA insiders buying or selling?
Have TYRA insiders filed to sell?
Who owns more than 5% of TYRA?
Which funds hold TYRA?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.